The Medicines and Healthcare products Regulatory Agency is responsible for monitoring all authorised medicines and vaccines in the United Kingdom, including the AstraZeneca COVID-19 vaccines, on an ongoing basis to ensure their benefits continue to outweigh any risks. This monitoring strategy is continuous, proactive, and based on a wide range of information sources, including reports of adverse events and rare side effects retrieved from the Yellow Card Database. A dedicated team of assessors reviews this information on a weekly basis to look for safety issues or unexpected, rare events.

The AstraZeneca COVID-19 vaccine no longer has an active market authorisation in the UK, since 2024. Consequently, no additional research activities have been undertaken beyond the ongoing monitoring of reported suspected adverse events through the Yellow Card Scheme. The most recent data extraction of spontaneous suspected adverse reactions reported via the Yellow Card Scheme was conducted on 20 September 2025. Further information is available at the following link:

https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19

The Medicines and Healthcare products Regulatory Agency is responsible for monitoring all authorised medicines and vaccines in the United Kingdom, including the AstraZeneca COVID-19 vaccines, on an ongoing basis to ensure their benefits continue to outweigh any risks. This monitoring strategy is continuous, proactive, and based on a wide range of information sources, including reports of adverse events and rare side effects retrieved from the Yellow Card Database. A dedicated team of assessors reviews this information on a weekly basis to look for safety issues or unexpected, rare events.

The AstraZeneca COVID-19 vaccine no longer has an active market authorisation in the UK, since 2024. Consequently, no additional research activities have been undertaken beyond the ongoing monitoring of reported suspected adverse events through the Yellow Card Scheme. The most recent data extraction of spontaneous suspected adverse reactions reported via the Yellow Card Scheme was conducted on 20 September 2025. Further information is available at the following link:

https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19

In the very rare event where an individual may have suffered a severe adverse reaction to a COVID-19 vaccine, care and treatment will be managed by National Health Service local specialist services, augmented as appropriate by national specialist advice, with any treatment dependent on the individual’s clinical needs.

The Government remains committed to research to improve the diagnosis and treatment in those rare cases where individuals may have suffered a severe adverse reaction to the COVID-19 vaccine.

Since the start of the pandemic, the National Institute for Health and Care Research (NIHR) has allocated more than £110 million of funding for COVID-19 vaccine research, including consideration of issues around vaccine safety. As part of this, the Department commissioned a £1.6 million programme of work through the NIHR, to understand the mechanisms underlying the occurrence of COVID-19 vaccine-induced thrombotic thrombocytopenia syndrome, a rare condition of blood clotting with low platelets following vaccination for COVID-19.

Vaccines are only authorised once they have met robust standards of effectiveness, safety, and quality set by the independent medicines’ regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).

The monitoring of vaccine safety does not stop once a vaccine has been approved. The MHRA continuously monitors safety data from a range of sources to ensure that the benefits continue to outweigh any risks. This includes reports of adverse events and rare side effects retrieved from the MHRA’s Yellow Card Database, interim and final study reports for clinical trials, post-authorisation safety studies, and data from scientific literature. A dedicated team of assessors reviews this information on a weekly basis to look for safety issues or unexpected, rare events.

The Department also commissions research through the National Institute for Health and Care Research (NIHR) and continues to welcome funding applications for research into any aspect of human health, including for vaccine side effects.

Since the start of the pandemic, the NIHR has allocated more than £110 million of funding for COVID-19 vaccine research, including consideration of issues around vaccine safety. As part of this, the Department commissioned a £1.6 million programme of work through the NIHR to understand the mechanisms underlying the occurrence of COVID-19 vaccine-induced thrombotic thrombocytopenia syndrome, a rare condition of blood clotting with low platelets following vaccination for COVID-19. This research was published in July 2025 and is available in the NIHR Journals Library.

Vaccines are only authorised once they have met robust standards of effectiveness, safety, and quality set by the independent medicines’ regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).

The monitoring of vaccine safety does not stop once a vaccine has been approved. The MHRA continuously monitors safety data from a range of sources to ensure that the benefits continue to outweigh any risks. This includes reports of adverse events and rare side effects retrieved from the MHRA’s Yellow Card Database, interim and final study reports for clinical trials, post-authorisation safety studies, and data from scientific literature. A dedicated team of assessors reviews this information on a weekly basis to look for safety issues or unexpected, rare events.

The Department also commissions research through the National Institute for Health and Care Research (NIHR) and continues to welcome funding applications for research into any aspect of human health, including for vaccine side effects.

Since the start of the pandemic, the NIHR has allocated more than £110 million of funding for COVID-19 vaccine research, including consideration of issues around vaccine safety. As part of this, the Department commissioned a £1.6 million programme of work through the NIHR to understand the mechanisms underlying the occurrence of COVID-19 vaccine-induced thrombotic thrombocytopenia syndrome, a rare condition of blood clotting with low platelets following vaccination for COVID-19. This research was published in July 2025 and is available in the NIHR Journals Library.

In the very rare event where someone may have suffered a severe adverse reaction to a vaccine, care and treatment will be best managed by local National Health Service specialist services, augmented as appropriate by national specialist advice. Individuals will be treated and managed through existing healthcare services, with treatment dependent on the individual’s clinical needs.

Individuals can also apply to the Vaccine Damage Payment Scheme (VDPS) which provides a one-off, tax-free payment of £120,000 to claimants who have been found, on the balance of probabilities, to have been severely disabled as a result of vaccinations against certain diseases listed in the Vaccine Damage Payments Act 1979.

Outside of the VDPS, other Government support remains available for those with a disability or long-term health condition, including Statutory Sick Pay, Universal Credit, Employment and Support Allowance, Attendance Allowance, and Personal Independence Payments. Further information is available at the following link:

https://www.gov.uk/browse/benefits/disability

Company feedback on Government grant process continually informs improvements in grant delivery. However, to maintain confidentiality between companies and Government, we do not publish company specific feedback.

Due to commercial confidentiality considerations, we are unable to place the requested letter in the House of Commons Library. As with any application for Government grant funding of this nature, all cases undergo rigorous due diligence, which assesses whether the investment represents good value for money for the taxpayer.

The Government remains committed to improving the business environment for Life Sciences companies. We continue to engage positively with AstraZeneca on the new Industrial Strategy and Life Sciences Sector Plan, due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector.

AstraZeneca’s decision not to invest in Speke is deeply disappointing. The Government regularly reviews it’s grant process and routinely seeks applicant feedback. The Government also continues to engage positively with AstraZeneca, including on the new Industrial Strategy and Life Sciences Sector Plan, due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector. Support includes the Life Sciences Innovative Manufacturing Fund, which will allocate up to £520 million to deliver economic growth and build health resilience.

The Government supports the vibrant life sciences sector, which contributes £108 billion to the economy and 300,000 jobs nationwide. A new Life Sciences Sector Plan, part of the upcoming Industrial Strategy, is due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector. In addition, the Life Sciences Innovative Manufacturing Fund will allocate up to £520 million to deliver economic growth and build health resilience, and is available UK-wide, including to projects in the Liverpool City region

AstraZeneca’s decision not to invest in Speke is deeply disappointing. The Government regularly reviews it’s grant process and routinely seeks applicant feedback. The Government also continues to engage positively with AstraZeneca, including on the new Industrial Strategy and Life Sciences Sector Plan, due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector. Support includes the Life Sciences Innovative Manufacturing Fund, which will allocate up to £520 million to deliver economic growth and build health resilience.

The Government has had numerous discussions with AstraZeneca about their proposed investment into Speke. There were minor delays in replying to correspondence following the election period.

The Minister for Data Protection and Telecoms is content to write a letter responding to the hon. Member for Harpenden and Berkhamsted on this matter in due course.

My department and I are closely engaged with AstraZeneca as we develop our new modern industrial strategy, which will focus on the sectors with the highest growth opportunity for the economy, including Life Sciences. As part of our engagement, we have had regular discussions with AstraZeneca on vaccine production in Speke.

The Government cannot comment on the terms on which COVID-19 vaccinations were procured, which are confidential.

The Conservatives secured a £450 million investment from AstraZeneca to expand its Merseyside vaccine factory. When the Chancellor wrecked the deal, AstraZeneca tried to save it by increasing that investment to over £500 million. Why did Labour still walk away, handing jobs and investment to our competitors?

When Labour negotiates, Britain loses. AstraZeneca is investing more than £4 billion in Singapore, the US and Canada. It could have invested in our country too. What is Labour doing to bring back the deal that it destroyed?